Who Paid My Doc
Amr El Meligy
Cardiovascular Disease Keene, NH Medical Doctor
NPI 1538543756 CMS profile 1330697
580 Court St, Keene, NH 03431
General payments
$5,304
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amr El Meligy of Keene, NH is reported in the CMS Open Payments database as having received $5,304 across 166 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $84 | 2 | |
| 2023 | General | $60 | 3 | |
| 2022 | General | $410 | 21 | |
| 2021 | General | $2,814 | 49 | |
| 2020 | General | $813 | 34 | |
| 2019 | General | $1,123 | 57 |
Beside peers
- Amr El Meligy
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Amr El Meligy were reported at $84. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Amr El Meligy | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,123 | $450 | $127–$1,392 | $163 |
| 2020 | $813 | $242 | $77–$751 | $114 |
| 2021 | $2,814 | $335 | $101–$1,037 | $132 |
| 2022 | $410 | $395 | $121–$1,211 | $149 |
| 2023 | $60 | $443 | $136–$1,283 | $160 |
| 2024 | $0 | $450 | $136–$1,323 | $164 |
| 2025 | $84 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
3,469
Drug cost
$471,915
Branded share of claims
25.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 430 | $269,125 | |
| Jardiance Empagliflozin | Brand | 68 | $59,503 | |
| Xarelto Rivaroxaban | Brand | 52 | $46,584 | |
| Entresto Sacubitril/Valsartan | Brand | 54 | $37,807 | |
| Repatha Sureclick Evolocumab | Brand | 26 | $20,427 | |
| Metoprolol Succinate | Generic | 541 | $7,433 | |
| Atorvastatin Calcium | Generic | 402 | $3,981 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 76 | $3,093 | |
| Ezetimibe | Generic | 125 | $2,446 | |
| Rosuvastatin Calcium | Generic | 124 | $1,806 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 53 billing codesPaid by Medicare
$99,977
Medicare patients
1,851
Services billed
3,251
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| Ischemic heart disease | 42% | |
| Atrial fibrillation | 37% | |
| Heart failure | 34% | |
| Depression | 31% | |
| Diabetes | 29% | |
| Chronic kidney disease | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
166 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in New Hampshire
Fahad Gilani
Cardiovascular Disease · Manchester, NH
Stephan Heo
Cardiovascular Disease · Manchester, NH
Robert Capodilupo
Cardiovascular Disease · Manchester, NH
Kevin Kwaku
Cardiovascular Disease · Lebanon, NH
Michael Young
Cardiovascular Disease · Lebanon, NH
Jeanney Lew
Cardiovascular Disease · Manchester, NH
Related records
Cardiovascular Disease in New Hampshire
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Hampshire
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.